Breast Cancer Res. 2007;9(5):110.

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.

Source

Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. emayer@partners.org

Abstract

Neoadjuvant chemotherapy for breast cancer has a well-established role in the management of patients with locally advanced or early stage disease. Multiple trials have demonstrated superior survival outcomes in individuals achieving a pathologic complete response at the time of definitive surgery, and sophisticated genetic methods may predict which patients will be in this category. Those with less than a pathologic complete response remain at significant risk of recurrent disease, and currently no further standard therapy exists. Ongoing studies of novel agents may lead to improved therapeutic outcomes for this high-risk population.

PMID:: 17888189; [PubMed - indexed for MEDLINE]
PMCID: PMC2242653

Free PMC Article

Images from this publication.See all images (1) Free text

Publication Types, MeSH Terms

Publication Types

Editorial

MeSH Terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Breast Cancer - MedlinePlus Health Information

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Review Overview of resistance to systemic therapy in patients with breast cancer. [Adv Exp Med Biol. 2007]
Review Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Adv Exp Med Biol. 2007; 608:1-22.
Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. [Cancer J. 2006]
Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.
Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA. Cancer J. 2006 May-Jun; 12(3):212-21.
MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. [Cancer. 2008]
MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY. Cancer. 2008 Jan 1; 112(1):17-26.
Review Breast cancer, neoadjuvant chemotherapy and residual disease. [Clin Transl Oncol. 2010]
Review Breast cancer, neoadjuvant chemotherapy and residual disease.
Chávez-MacGregor M, González-Angulo AM. Clin Transl Oncol. 2010 Jul; 12(7):461-7.
Review Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. [Expert Opin Pharmacother. 2004]
Review Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer.
Heys SD, Sarkar T, Hutcheon AW. Expert Opin Pharmacother. 2004 Oct; 5(10):2147-57.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC

Recent activity

Clear Turn Off Turn On

Clinical trial update: implications and management of residual disease after neo...
Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.
Breast Cancer Res. 2007 ;9(5):110.

PubMed
Prospects for whole-genome linkage disequilibrium mapping of common disease gene...
Prospects for whole-genome linkage disequilibrium mapping of common disease genes.
Nat Genet. 1999 Jun ;22(2):139-44.

PubMed
Cytoplasmic sequestration and functional repression of p53 in the mammary epithe...
Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment.
Cancer Res. 2000 May 15 ;60(10):2723-9.

PubMed
Radiologic tests after a new diagnosis of breast cancer.
Radiologic tests after a new diagnosis of breast cancer.
Eff Clin Pract. 2000 Jan-Feb ;3(1):1-6.

PubMed
The expression level of HJURP has an independent prognostic impact and predicts ...
The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.
Breast Cancer Res. 2010 ;12(2):R18. Epub 2010 Mar 8 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: